Design Therapeutics Inc.

27.57+0.4800+1.77%Vol 258.60K1Y Perf -33.15%
Jun 14th, 2021 16:00 DELAYED
BID27.57 ASK27.80
Open27.44 Previous Close27.09
Pre-Market- After-Market-
 - -  - -%
Target Price
39.00 
Analyst Rating
— — 0.00
Potential %
41.46 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap1.53B 
Earnings Rating
Price Range Ratio 52W %
28.23 
Earnings Date
-

Today's Price Range

27.0728.43

52W Range

18.5550.50

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
-0.14%
1 Month
19.92%
3 Months
-
6 Months
-
1 Year
-33.15%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
DSGN27.570.48001.77
AAPL130.483.13002.46
GOOG2 527.0413.11000.52
MSFT259.892.00000.78
XOM62.07-0.1000-0.16
WFC45.15-0.5300-1.16
JNJ165.370.41000.25
FB336.775.51001.66
GE13.47-0.2200-1.61
JPM157.57-2.7200-1.70
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.06-0.31-416.67
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume258.60K
Shares Outstanding55.62M
Trades Count3.15K
Dollar Volume0
Avg. Volume144.34K
Avg. Weekly Volume100.56K
Avg. Monthly Volume85.88K
Avg. Quarterly Volume144.34K

Design Therapeutics Inc. (NASDAQ: DSGN) stock closed at 27.57 per share at the end of the most recent trading day (a 1.77% change compared to the prior day closing price) with a volume of 258.60K shares and market capitalization of 1.53B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 20 people. Design Therapeutics Inc. CEO is Joao Siffert.

The one-year performance of Design Therapeutics Inc. stock is -33.15%, while year-to-date (YTD) performance is %. DSGN stock has a five-year performance of %. Its 52-week range is between 18.55 and 50.5, which gives DSGN stock a 52-week price range ratio of 28.23%

Design Therapeutics Inc. currently has a PE ratio of -46.30, a price-to-book (PB) ratio of 3.69, a price-to-sale (PS) ratio of 18 254.40, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -3.19%, a ROC of -3.22% and a ROE of -3.22%. The company’s profit margin is -%, its EBITDA margin is -15 926.20%, and its revenue ttm is $84.00 Thousand , which makes it $0.00 revenue per share.

Of the last four earnings reports from Design Therapeutics Inc., there were 0 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Design Therapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Design Therapeutics Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Design Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Design Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Design Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 35.34, ATR14 : 1.93, CCI20 : 106.21, Chaikin Money Flow : 0.08, MACD : 0.47, Money Flow Index : 57.77, ROC : 3.76, RSI : 54.40, STOCH (14,3) : 77.64, STOCH RSI : 0.94, UO : 48.77, Williams %R : -22.36), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Design Therapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Design Therapeutics Inc.

Design Therapeutics Inc is a preclinical-stage biopharmaceutical company. It is pioneering novel small-molecule therapeutic candidates, called gene targeted chimeras, that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases.

CEO: Joao Siffert

Telephone: +1 858 293-4900

Address: 6005 Hidden Valley Road, Carlsbad 92011, CA, US

Number of employees: 20

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

50%50%

News

Stocktwits